Brief: Envista Q2 Sales USD 682.1 Million Vs. IBES Estimate USD 640.2 Million

Envista Holdings

31/07/2025 21:05

Overview

Envista Q2 sales beat analyst expectations, reaching $682 mln, per LSEG data

Adjusted EPS for Q2 rises 136% yr/yr, reflecting strong profitability

Co raises full-year 2025 guidance, indicating confidence in continued growth

Outlook

Envista raises 2025 core sales growth guidance to 3%-4%

Company increases 2025 adjusted EPS guidance to $1.05-$1.15

Envista maintains 2025 adjusted EBITDA margin guidance at ~14%

Result Drivers

GEOGRAPHIC GROWTH - Positive growth across all major businesses and geographies, including Nobel Biocare in North America

OPERATIONAL IMPROVEMENTS - Envista Business System (EBS) contributed to continued improvement in Spark margins

EMPLOYEE ENGAGEMENT - Sustained improvement in employee engagement and development, as noted by the company

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Sales
Beat
$682.10 mln
$640.20 mln (12 Analysts)
Q2 Adjusted Net Income
$44 mln
Q2 Net Income
$26 mln
Q2 Adjusted EBITDA
$84 mln
Q2 Gross Profit
$369.90 mln
Q2 Operating Profit
$46.30 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 9 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for Envista Holdings Corp is $20.00, about 0.2% above its July 30 closing price of $19.96

The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release: ID:nPn6LJQHZa

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)